玛贝兰妥单抗相关眼部不良事件临床管理指导原则(2026年版)
Guiding principles for clinical management of belantamab mafodotin-related ocular adverse events (2026 version)
摘要
玛贝兰妥单抗是复发难治多发性骨髓瘤(MM)患者的有效治疗选择。眼部不良事件是玛贝兰妥单抗的常见不良反应,经专业培训的医师可通过规范管理,最大限度降低其对患者的不良影响。基于玛贝兰妥单抗相关眼部不良事件的临床试验数据、真实世界证据等,专家组讨论制定了玛贝兰妥单抗相关眼部不良事件的识别、监测与临床管理建议,并提供剂量调整指导方案,期望提升药物临床应用的便捷性,改善患者预后。本指导原则适用于所有接受玛贝兰妥单抗联合方案治疗的MM患者,包括中等体能或体弱患者。
Belantamab mafodotin is an effective therapeutic option for patients with relapsed/refractory multiple myeloma (MM). Ocular adverse events represent the frequent treatment-related side effects of belantamab mafodotin, and standardized clinical management by professionally trained physicians can minimize their adverse impacts on patients. Based on clinical trial data, real-world evidence and other available evidence related to belantamab mafodotin-related ocular adverse events, the expert panel discussed and developed recommendations for the recognition, monitoring and clinical management of belantamab mafodotin-related ocular adverse events, together with guidance on dose modifications. These recommendations are intended to facilitate the clinical use of belantamab mafodotin and improve the outcomes of patients. These guiding principles apply to all the MM patients using belantamab mafodotin-containing regimens, including frail and elderly patients.
年,卷(期):
2026, 35(7)
在线出版日期:
2026年7月25日